CSIMarket
 


Odonate Therapeutics Inc   (ODT)
Other Ticker:  
 

Cumulative Odonate Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

ODT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ODT Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Current Liabilities Growth 6.17 % 16.02 % 32.15 % 9.26 % 15.22 %
Y / Y Current Assets Growth -47.79 % -12.31 % -13.4 % -13.08 % -8.4 %
Working Capital Ratio for Trailing Twelve Months Period 4.23 5.06 5.38 5.98 6.35
Total Ranking # 1191 # 957 # 877 # 663 # 566
Seq. Current Liabilities Growth 2.18 % -10.41 % 22.24 % -5.12 % 11.66 %
Seq. Current Assets Growth -11.14 % -17.66 % -14.87 % -16.18 % 49.23 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2021
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $30 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 4.23 below Odonate Therapeutics Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 356 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Odonate Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ODT
Working Capital Ratio ODT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 357
Sector # 641
S&P 500 # 1440


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
17.27 6.92 0.47
(Mar 31 2018)   (Dec 31 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Aurinia Pharmaceuticals Inc   11.50 
Morphic Holding inc   11.38 
Syndax Pharmaceuticals Inc   11.23 
Larimar Therapeutics Inc   11.22 
Zai Lab Limited  11.20 
Bolt Biotherapeutics Inc   10.96 
Gracell Biotechnologies Inc   10.89 
Zentalis Pharmaceuticals Inc   10.80 
Protokinetix Incorporated  10.73 
Sio Gene Therapies Inc   10.71 
Renovaro Inc   10.70 
Schrodinger Inc   10.68 
Cara Therapeutics inc   10.64 
Trevena inc   10.43 
Homology Medicines Inc  10.38 
Cytokinetics Incorporated  10.37 
Ac Immune Sa  10.12 
Ascendis Pharma A  10.09 
Mirati Therapeutics Inc   10.09 
Scpharmaceuticals Inc   9.88 
Siga Technologies Inc  9.88 
Alzamend Neuro Inc   9.83 
Frequency Therapeutics Inc   9.80 
Marinus Pharmaceuticals Inc   9.79 
Kiniksa Pharmaceuticals ltd   9.75 
Corcept Therapeutics Inc  9.71 
Contrafect Corporation  9.67 
United Therapeutics Corporation  9.66 
Phio Pharmaceuticals Corp   9.62 
Immunome Inc  9.59 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com